Bååth, M., Westbom-Fremer, S., Martin de la Fuente, L., Ebbesson, A., Davis, J., Malander, S., . . . Hedenfalk, I. (2020). SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery. Mol Cell Oncol.

Bååth, Maria, Sofia Westbom-Fremer, Laura Martin de la Fuente, Anna Ebbesson, Juliette Davis, Susanne Malander, Anna Måsbäck, Päivi Kannisto, και Ingrid Hedenfalk. "SOX2 Is a Promising Predictor of Relapse and Death in Advanced Stage High-grade Serous Ovarian Cancer Patients With Residual Disease After Debulking Surgery." Mol Cell Oncol 2020.

Bååth, Maria, et al. "SOX2 Is a Promising Predictor of Relapse and Death in Advanced Stage High-grade Serous Ovarian Cancer Patients With Residual Disease After Debulking Surgery." Mol Cell Oncol 2020.